Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ricasetron SCHEMBL21715163 | 1.00 | NOTUM (0.52) | NOTUMCNR2TMEM97SIGMAR1HTR3A | |
| Ricasetron SCHEMBL20362251 | 1.00 | NOTUM (0.52) | NOTUMCNR2TMEM97SIGMAR1HTR3A | |
| Ricasetron SCHEMBL634826 | 1.00 | NOTUM (0.52) | NOTUMCNR2TMEM97SIGMAR1HTR3A | |
| Ricasetron SCHEMBL7445859 | 0.99 | NOTUM (0.51) | NOTUMCNR2TMEM97SIGMAR1HTR3A | |
| SCHEMBL7295216 | 0.91 | NOTUM (0.50) | NOTUMCNR2HTR3A | |
| SCHEMBL9368172 | 0.82 | TMEM97 (0.45) | TMEM97SIGMAR1HTR3AHTR4 | |
| SCHEMBL9602391 | 0.81 | MEN1 (0.42) | NOTUM | |
| SCHEMBL7624884 | 0.81 | CNR2 (0.48) | NOTUMCNR2HTR3A | |
| SCHEMBL7624888 | 0.81 | CNR2 (0.48) | NOTUMCNR2HTR3A | |
| Ethane SCHEMBL7627590 | 0.80 | CNR2 (0.47) | NOTUMCNR2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3691637-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE Pharmaceuticals GmbH (AT) | 2020-08-12 | — | — | EP | claimed |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2020-08-06 | — | — | US | claimed |
| WO-2019068904-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2019-04-11 | — | — | WO | claimed |
| WO-2016118540-A1 | TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR EMESIS | Xoc Pharmaceuticals, Inc. (US) | 2016-07-28 | — | — | WO | claimed |
| US-5246941-A | Serotonin antagonist | GLAXO GROUP LIMITED (GB) | 1993-09-21 | — | — | US | claimed |
| EP-0553160-A1 | USE OF ENDO-N-(8-METHYL-8-AZABICYCLO 3.2.1]oct-3-yl)-2,3-DIHYDRO-3,3DIMETHYLINDOLE-1-CARBOXAMIDE IN THE TREATMENT OF DEPENDENCE AND WITHDRAWAL SYNDROME | Beecham Group p.l.c. (GB) | 1993-08-04 | — | — | EP | claimed |
| US-5198447-A | Aid for withdrawal from drugs, alcohol, cigarettes | GLAXO GROUP LIMITED (GB) | 1993-03-30 | — | — | US | claimed |
| EP-0247266-B1 | INDOLE DERIVATIVES HAVING AN AZABICYCLIC SIDE CHAIN, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1993-03-10 | — | — | EP | claimed |
| EP-0340270-B1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICTION | BEECHAM GROUP PLC (GB) | 1992-07-15 | — | — | EP | claimed |
| WO-1992006689-A1 | USE OF ENDO-N-(8-METHYL-8-AZABICYCLO[3.2.1]oct-3-yl)-2,3-DIHYDRO-3,3DIMETHYLINDOLE-1-CARBOXAMIDE IN THE TREATMENT OF DEPENDENCE AND WITHDRAWAL SYNDROME | BEECHAM GROUP PLC (GB) | 1992-04-30 | — | — | WO | claimed |
| EP-0450757-A2 | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | GLAXO GROUP LIMITED (GB) | 1991-10-09 | — | — | EP | claimed |
| US-4942160-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | BEECHAM GROUP P.L.C. (GB) | 1990-07-17 | — | — | US | claimed |
| EP-0279512-A2 | Use of certain 5-HT3 receptor antagonists in the treatment of visceral pain | BEECHAM GROUP PLC (GB) | 1988-08-24 | — | — | EP | claimed |
| EP-0247266-A1 | Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1987-12-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | NOTUM 3195/4885CNR2 834/4885TMEM97 1320/4885 |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | ABCB1, MTHFD1, BHMT | NOTUM 987/4885CNR2 914/4885TMEM97 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.